Madrid

• Master Protocol for Avelumab Continuation Study. Ended recruitment
  2023-509466-38-00 5 2022-03-08 Cancer
• A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Ended recruitment
  2024-512148-50-00 5 2022-03-03 Non-small cell lung cancer
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged ≥ 1 to < 7 Years with Neurofibromatosis Type 1 … Ended recruitment
  2023-506357-38-00 9 2022-02-17 Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
• Postmarketing Parallel Randomized Clinical Trial to Determine the Efficacy and Safety of Atropine and DIMS Lenses in the Control of Myopia i … Ended recruitment
  2024-514651-15-00 6 2022-02-16 Myopia
• Assessment of effectiveness and safety of luspatercept in patients suffering from lower-risk myelodysplastic syndrome. Ended recruitment
  2024-515069-33-00 5 2022-02-15 Patients with anemia due to IPSS-R defined very low-, low-, or interme
• A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s … Ended recruitment
  2023-503868-16-00 5 2022-02-14 Small-Cell Lung Cancer (SCLC)
• An Open-Label Extension and Safety Monitoring Study of Acoramidis(AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopath … Ended recruitment
  2024-515092-36-00 5 2022-02-14 Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I … Ended recruitment
  2024-515617-18-00 1 2022-02-14 Advanced clear cell renal cell carcinoma (ccRCC), non-clear cell renal
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu … Ended recruitment
  2023-506516-40-00 5 2022-02-11 Relapsing-Remitting Multiple Sclerosis
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Stan … Ended recruitment
  2024-518266-27-00 5 2022-02-02 Niemann Pick Disease Type C1
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa … Ended recruitment
  2024-518304-53-00 5 2022-02-02 Relapsed or Refractory Multiple Myeloma (RRMM)
• Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended recruitment
  2024-510655-36-00 7 2022-02-01 Advanced Malignancies Associated with EphA2 Expression
• Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended recruitment
  2023-509441-13-00 4 2022-01-31 Warm autoimmune hemolytic anemia
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509372-41-00 5 2022-01-30 Multiple Sclerosis
• A research study to find out if the study treatment alpelisib (BYL719) is safe for a long period of time for who has confirmed diagnosis of … Ended recruitment
  2023-508522-95-00 4 2022-01-27 PIK3CA-Related Overgrowth Spectrum (PROS)
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended recruitment
  2023-506867-33-01 4 2022-01-25 Chronic Hepatitis B
• A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended recruitment
  2023-509406-30-00 10 2022-01-24 Patients with HER2-overexpressing advanced or metastatic gastric or ga
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca … Ended recruitment
  2023-509631-37-00 5 2022-01-18 "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
• A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 in subjects with Advanced Systemic Mastocy … Ended recruitment
  2024-511407-42-00 4 2022-01-10 Advanced Systemic Mastocytosis
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved … Ended recruitment
  2023-506986-74-00 9 2021-12-27 B-cell non-Hodgkin lymphoma (NHL)
• A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended recruitment
  2024-511599-33-00 5 2021-12-22 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Showing 2,209–2,232 of 3,550 trials